Biomarkers for Evaluation of Clinical Efficacy of Multipotential Neuroprotective Drugs for Alzheimer's and Parkinson's Diseases

Neurotherapeutics

Volumn 6, Issue 1, 2009, Pages 128-140

  Halperin, Ilan ^a   Morelli, Micaela ^b   Korczyn, Amos D ^c   Youdim, Moussa B H ^d   Mandel, Silvia A ^d  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c TEL AVIV UNIVERSITY   (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Alzheimer's disease; biomarker; disease modifying therapies; neuroimaging; neuroprotective drugs; Parkinson's disease

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 6 FLUORODOPA F 18; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; DJ 1 PROTEIN; FLUORODEOXYGLUCOSE F 18; IODINE 123; NEUROPROTECTIVE AGENT; PRESENILIN 1; PRESENILIN 2; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; AUTONOMIC DYSFUNCTION; CEREBROSPINAL FLUID; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OLFACTORY NERVE DISEASE; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER;

ALZHEIMER DISEASE; ANTIPARKINSON AGENTS; AUTONOMIC NERVOUS SYSTEM; BIOLOGICAL MARKERS; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 57749108323     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.10.033     Document Type: Article

References (102)

1. Fratiglioni L., Launer L.J., Andersen K., et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54 (2000) S10-S15
2. Lobo A., Launer L.J., Fratiglioni L., et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54 (2000) S4-S9
3. Graham J.E., Rockwood K., Beattie B.L., et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 349 (1997) 1793-1796
4. Poewe W., and Wenning G. The differential diagnosis of Parkinson's disease. Eur J Neurol 9 Suppl 3 (2002) 23-30
5. Galasko D., Hansen L.A., Katzman R., et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 51 (1994) 888-895
6. Hulette C., Nochlin D., McKeel D., et al. Clinical-neuropathologic findings in multi-infarct dementia: a report of six autopsied cases. Neurology 48 (1997) 668-672
7. Lyketsos C.G., Szekely C.A., Mielke M.M., Rosenberg P.B., and Zandi P.P. Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies. Int Psychogeriatr 20 (2008) 871-889
8. Kawas C., Gray S., Brookmeyer R., Fozard J., and Zonderman A. Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 54 (2000) 2072-2077
9. Youdim M.B. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Curr Alzheimer Res 3 (2006) 541-550
10. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
11. Sunderland T., Hampel H., Takeda M., Putnam K.T., and Cohen R.M. Biomarkers in the diagnosis of Alzheimer's disease: are we ready?. J Geriatr Psychiatry Neurol 19 (2006) 172-179
12. Clark C.M., Davatzikos C., Borthakur A., et al. Biomarkers for early detection of Alzheimer pathology. Neurosignals 16 (2008) 11-18
13. Halperin I., and Korczyn A.D. [Mild cognitive impairment (MCI): characteristics, risk factors and prevention]. Harefuah 145 (2006) 229-234 243
14. Hänninen T., Hallikainen M., Tuomainen S., Vanhanen M., and Soininen H. Prevalence of mild cognitive impairment: a population-based study in elderly subjects. Acta Neurol Scand 106 (2002) 148-154
15. Bertram L., and Tanzi R.E. The current status of Alzheimer's disease genetics: what do we tell the patients?. Pharmacol Res 50 (2004) 385-396
16. Tanzi R.E., and Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 32 (2001) 181-184
17. Mulder C., Scheltens P., Visser J.J., van Kamp G.J., and Schutgens R.B. Genetic and biochemical markers for Alzheimer's disease: recent developments. Ann Clin Biochem 37 Pt 5 (2000) 593-607
18. Otto M., Lewczuk P., and Wiltfang J. Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. Methods 44 (2008) 289-298
19. Corder E.H., Saunders A.M., Strittmatter W.J., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 921-923
20. Resnick S.M., Goldszal A.F., Davatzikos C., et al. One-year age changes in MRI brain volumes in older adults. Cereb Cortex 10 (2000) 464-472
21. Sullivan E.V., Pfefferbaum A., Adalsteinsson E., Swan G.E., and Carmelli D. Differential rates of regional brain change in callosal and ventricular size: a 4-year longitudinal MRI study of elderly men. Cereb Cortex 12 (2002) 438-445
22. Chetelat G., and Baron J.C. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. Neuroimage 18 (2003) 525-541
23. Borthakur A., Wheaton A.J., Gougoutas A.J., et al. In vivo measurement of T1rho dispersion in the human brain at 1.5 tesla. J Magn Reson Imaging 19 (2004) 403-409
24. Klunk W.E., Panchalingam K., Moossy J., McClure R.J., and Pettegrew J.W. N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer's disease brain: a preliminary proton nuclear magnetic resonance study. Neurology 42 (1992) 1578-1585
25. Kwo-On-Yuen P.F., Newmark R.D., Budinger T.F., Kaye J.A., Ball M.J., and Jagust W.J. Brain N-acetyl-L-aspartic acid in Alzheimer's disease: a proton magnetic resonance spectroscopy study. Brain Res 667 (1994) 167-174
26. Jessen F., Block W., Traber F., et al. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 55 (2000) 684-688
27. Schuff N., Capizzano A.A., Du A.T., et al. Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology 58 (2002) 928-935
28. Kantarci K., Jack Jr. C.R., Xu Y.C., et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology 55 (2000) 210-217
29. MacKay S., Ezekiel F., Di Sclafani V., et al. Alzheimer disease and subcortical ischemic vascular dementia: evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging. Radiology 198 (1996) 537-545
30. Kantarci K., Jack Jr. C.R., Xu Y.C., et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology 55 (2000) 210-217
31. Foster N.L., Heidebrink J.L., Clark C.M., et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 130 (2007) 2616-2635
32. Silverman D.H., Small G.W., Chang C.Y., et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 286 (2001) 2120-2127
33. Jagust W. Molecular neuroimaging in Alzheimer's disease. NeuroRx 1 (2004) 206-212
34. Johnson K.A., Holman B.L., Rosen T.J., Nagel J.S., English R.J., and Growdon J.H. Iofetamine I 123 single photon emission computed tomography is accurate in the diagnosis of Alzheimer's disease. Arch Intern Med 150 (1990) 752-756
35. Eberling J.L., Jagust W.J., Reed B.R., and Baker M.G. Reduced temporal lobe blood flow in Alzheimer's disease. Neurobiol Aging 13 (1992) 483-491
36. Johnson K.A., Jones K., Holman B.L., et al. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 50 (1998) 1563-1571
37. Archer H.A., Edison P., Brooks D.J., et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 60 (2006) 145-147
38. Engler H., Forsberg A., Almkvist O., et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129 (2006) 2856-2866
39. Jagust W., Thisted R., Devous Sr. M.D., et al. SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study. Neurology 56 (2001) 950-956
40. Shoji M., Golde T.E., Ghiso J., et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258 (1992) 126-129
41. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 1 (2004) 213-225
42. Blennow K., Vanmechelen E., and Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 24 (2001) 87-97
43. Clark C.M., Xie S., Chittams J., et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch Neurol 60 (2003) 1696-1702
44. Arai H., Nakagawa T., Kosaka Y., et al. Elevated cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired patients. Alzheimer's Research 3 (1997) 211-213
45. Schonknecht P., Pantel J., Hartmann T., et al. Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy. Psychiatry Res 120 (2003) 231-238
46. Hampel H., Buerger K., Kohnken R., et al. Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann Neurol 49 (2001) 545-546
47. Galasko D., Clark C., Chang L., Miller B., Green R.C., Motter R., and Seubert P. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology 48 (1997) 632-635
48. Samuels S.C., Silverman J.M., Marin D.B., et al. CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease. Neurology 52 (1999) 547-551
49. Hulstaert F., Blennow K., Ivanoiu A., et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52 (1999) 1555-1562
50. Andreasen N., Minthon L., Davidsson P., et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58 (2001) 373-379
51. Ringman J.M., Younkin S.G., Pratico D., et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 71 (2008) 85-92
52. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 23 (2000) S8-S19
53. Mandel S., Amit T., Kalfon L., and Youdim M.B. Applying transcriptomic and proteomic knowledge to Parkinson's disease drug discovery. Expert opinion on drug discovery 2 (2007) 1225-1240
54. Vendette M., Gagnon J.F., Decary A., et al. REM sleep behavior disorder predicts cognitive impairment in Parkinson's disease without dementia. Neurology 69 (2007) 1843-1849
55. Postuma R.B., Gagnon J.F., Vendette M., Charland K., and Montplaisir J. REM sleep behaviour disorder in Parkinson's disease is associated with specific motor features. J Neurol Neurosurg Psychiatry 79 (2008) 1117-1121
56. Burn D.J. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord 17 (2002) 445-454
57. Remy P., Doder M., Lees A., Turjanski N., and Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128 (2005) 1314-1322
58. McKinnon J.H., Demaerschalk B.M., Caviness J.N., Wellik K.E., Adler C.H., and Wingerchuk D.M. Sniffing out Parkinson disease: can olfactory testing differentiate parkinsonian disorders?. Neurologist 13 (2007) 382-385
59. Hudry J., Thobois S., Broussolle E., Adeleine P., and Royet J.P. Evidence for deficiencies in perceptual and semantic olfactory processes in Parkinson's disease. Chem Senses 28 (2003) 537-543
60. Montgomery Jr. E.B., Koller W.C., LaMantia T.J., et al. Early detection of probable idiopathic Parkinson's disease: I. Development of a diagnostic test battery. Mov Disord 15 (2000) 467-473
61. Montgomery Jr. E.B., Lyons K., and Koller W.C. Early detection of probable idiopathic Parkinson's disease: II. A prospective application of a diagnostic test battery. Mov Disord 15 (2000) 474-478
62. Troster A.I. Neuropsychological characteristics of dementia with Lewy bodies and Parkinson's disease with dementia: differentiation, early detection, and implications for "mild cognitive impairment" and biomarkers. Neuropsychol Rev 18 (2008) 103-119
63. Sommer C., and Lauria G. Skin biopsy in the management of peripheral neuropathy. Lancet Neurol 6 (2007) 632-642
64. Rossi A., Giovenali P., Benvenuti M., Di Iorio W., and Calabresi P. Skin biopsy: a new diagnostic tool for autonomic dysfunctions in Parkinson's disease?. Lancet Neurol 6 (2007) 848-849 author reply 849
65. Harrington M.G., and Merril C.R. Two-dimensional electrophoresis and "ultrasensitive" silver staining of cerebrospinal fluid proteins in neurological diseases. Clin Chem 30 (1984) 1933-1937
66. Nagai Y., Ueno S., Saeki Y., Soga F., Hirano M., and Yanagihara T. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology 46 (1996) 791-795
67. Barbanti P., Fabbrini G., Ricci A., et al. Increased expression of dopamine receptors on lymphocytes in Parkinson's disease. Mov Disord 14 (1999) 764-771
68. Caronti B., Antonini G., Calderaro C., et al. Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. J Neural Transm 108 (2001) 803-807
69. Parker Jr. W.D., Boyson S.J., and Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26 (1989) 719-723
70. Benecke R., Strumper P., and Weiss H. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain 116 Pt 6 (1993) 1451-1463
71. Haas R.H., Nasirian F., Nakano K., et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 37 (1995) 714-722
72. Migliore L., Petrozzi L., Lucetti C., et al. Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology 58 (2002) 1809-1815
73. Harrington M.G., Fonteh A.N., Biringer RG A.F.R.H., and Cowan R.P. Prostaglandin D synthase isoforms from cerebrospinal fluid vary with brain pathology. Dis Markers 22 (2006) 73-81
74. Davis J.W., Grandinetti A., Waslien C.I., Ross G.W., White L.R., and Morens D.M. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am J Epidemiol 144 (1996) 480-484
75. Weisskopf M.G., O'Reilly E., Chen H., Schwarzschild M.A., and Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 166 (2007) 561-567
76. Schwarzschild M.A., Schwid S.R., Marek K., et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 65 (2008) 716-723
77. Goldknopf I.L. Blood-based proteomics for personalized medicine: examples from neurodegenerative disease. Expert Rev Proteomics 5 (2008) 1-8
78. Sheta E.A., Appel S.H., and Goldknopf I.L. 2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases. Expert Rev Proteomics 3 (2006) 45-62
79. Goldknopf I.L., Sheta E.A., Bryson J., et al. Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease. Biochem Biophys Res Commun 342 (2006) 1034-1039
80. Zhang J., Sokal I., Peskind E.R., et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 129 (2008) 526-529
81. Gowers W.R. A manual of diseases of the nervous system (1888), P. Blakiston, Philadelphia pp. 1027-1049
82. Leroux P.-D. Contribution à l'étude des causes de la paralysie agitante. (in French). Thèse de Paris, imprimeur de la faculté de médecine (1880)
83. Rosner S., Giladi N., and Orr-Urtreger A. Advances in the genetics of Parkinson's disease. Acta Pharmacol Sin 29 (2008) 21-34
84. Mollenhauer B., Cullen V., Kahn I., et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213 (2008) 315-325
85. El-Agnaf O.M., Salem S.A., Paleologou K.E., et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. Faseb J 20 (2006) 419-425
86. Maita C., Tsuji S., Yabe I., et al. Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci Lett 431 (2008) 86-89
87. Waragai M., Wei J., Fujita M., et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun 345 (2006) 967-972
88. Waragai M., Nakai M., Wei J., et al. Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. Neurosci Lett 425 (2007) 18-22
89. Zetterberg H., Ruetschi U., Portelius E., et al. Clinical proteomics in neurodegenerative disorders. Acta Neurol Scand 118 (2008) 1-11
90. Brooks D.J. Technology insight: imaging neurodegeneration in Parkinson's disease. Nat Clin Pract Neurol 4 (2008) 267-277
91. Eckert T., Tang C., and Eidelberg D. Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol 6 (2007) 926-932
92. Berg D. Biomarkers for the early detection of Parkinson's and Alzheimer's disease. Neurodegener Dis 5 (2008) 133-136
93. Berg D., Siefker C., and Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 248 (2001) 684-689
94. Berg D., Roggendorf W., Schroder U., et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59 (2002) 999-1005
95. Zecca L., Youdim M.B., Riederer P., Connor J.R., and Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5 (2004) 863-873
96. Koeppen A.H. The history of iron in the brain. J Neurol Sci 134 Suppl (1995) 1-9
97. Braak H., Muller C.M., Rub U., et al. Pathology associated with sporadic Parkinson's disease-where does it end?. J Neural Transm Suppl (2006) 89-97
98. Sullivan P.F., Fan C., and Perou C.M. Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 141B (2006) 261-268
99. Burczynski M.E., and Dorner A.J. Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics 7 (2006) 187-202
100. Glatt S.J., Everall I.P., Kremen W.S., et al. Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proc Natl Acad Sci U S A 102 (2005) 15533-15538
101. Scherzer C.R., Eklund A.C., Morse L.J., et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A 104 (2007) 955-960
102. Scherzer C.R., Grass J.A., Liao Z., et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A 105 (2008) 10907-10912